NET PROFIT FORECAST: Net profit is expected to rise to 1.67 billion pounds from 1.05 billion pounds, according to a consensus provided by the company. London-listed shares in GSK are up 4.1% since the ...

British pharmaceutical giant GSK has not met required ethical and regulatory standards in the marketing and prescription ...

GSK’s blood cancer drug Blenrep won regulatory approval in the U.K., marking the medicine’s return to the market after it was ...

With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...

GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities ...

We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Nucala, Ojjaara, Jemperli and Trelegy Ellipta to have driven first-quarter sales performance.

Some justices may be skeptical of a bid by GSK, Pfizer and others to overturn ruling allowing lawsuits to proceed over claims ...

The UK on Thursday authorized GSK’s Blenrep to treat certain multiple myeloma patients in two different regimens, marking the drug’s first approval worldwide since it was pulled from the US and other ...

Pharmaceutical companies in China report importing drugs with tariff exemptions, indicating possible flexibility from Chinese ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. | GSK has secured the first regulatory approval for Blenrep since the ...

April 17 (Reuters) - GSK (GSK.L), opens new tab said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities for the treatment of a ...